Introduction
============

The manipulation of the rumen microbial ecosystem using plant secondary compounds has proved to be a useful strategy to increase the efficiency of feed utilization by ruminants ([@B1]; [@B27]). Plants or their extracts with high concentrations of saponins appear to have the potential to act as natural antiprotozoal agents ([@B17]). Protozoa are a normal but non-vital part of the rumen microbiome and can contribute up to 50% of the bio-mass in the rumen ([@B28]). Because of their predation activity, rumen protozoa have been shown to be highly active in the turnover of bacterial protein in the rumen ([@B26]). Moreover, protozoa have been proven to harbor an active population of methanogenic archaea both on their external and internal surfaces ([@B5]; [@B16]). A recent meta-analysis has shown that the elimination of protozoa from the rumen could increase microbial protein supply to the host by up to 30% and reduce methane production by up to 11% ([@B14]).

Saponins are plant secondary metabolites which consist of one or more sugar moieties glycosidically linked to a less polar aglycone or sapogenin ([@B6]). The sugar portion is generally made up of common monosaccharides, such as D-glucose, D-galactose, D-glucuronic acid, D-xylose, L-rhamnose, and various pentoses which are glycosidically linked as linear or branched oligosaccharides to the sapogenin. Saponins can be broadly classified based on their sapogenin structure as either triterpenoid or steroid saponins ([@B29]). The presence of different substituents in the sapogenin such as hydroxyl, hydroxymethyl, carboxyl, and acyl groups, as well as differences in the composition, linkage and number of sugar chains accounts for significant structural variation and thus their bioactivity ([@B18]; [@B19]).

Saponins can form irreversible complexes with cholesterol in the protozoal cell membrane causing cell rupture and lysis ([@B29]). Rumen protozoal species seems to differ in their sensitivity to saponins due to differences in the sterol composition of their cellular membranes leading to the suggestion that feeding saponins might lead to partial defaunation ([@B17]). The antiprotozoal effect of saponins is, however, transitory as when saponins are deglycosylated by rumen microorganisms to the sapogenin they become inactive ([@B15]; [@B17]) which represents a challenge to their practical application in ruminant nutrition. We hypothesized that the substitution of the sugar moiety of the saponin with small polar residues would produce sapogen-like analogs which might be resistant to degradation in the rumen as they would not be enzymatically cleaved, allowing the antiprotozoal effect to persist over time. The aim of this study was to evaluate both the acute anti-protozoal action and the stability of the antiprotozoal effect of chemically synthesized hederagenin, cholesterol, and cholic acid derivatives *in vitro.*

Materials and Methods {#s1}
=====================

Hederagenin, Cholesterol, and Cholic Acid Derivatives
-----------------------------------------------------

Ripe ivy (*Hedera helix*) fruits were collected from several locations around Bangor (44.8036° N, 68.7703° W, UK), dried at 50°C for 2 days and milled. Ivy fruit meal (3.79 kg) was extracted with ethanol (15 L) for 6 h, leading to a crude extract (541 g) comprising triglycerides, saponins, oligosaccharides, and pigments (anthocyanins). The crude extract was then washed with petroleum ether (3 × 500 mL) and dried overnight at 50°C under vacuum, obtaining a fine powder (368 g) which comprised mainly mixed saponins and oligosaccharides. Then an additional extraction with *n*-butanol was carried out, obtaining a refined extract comprising saponins (15% DM). Hederagenin, the aglycone part of the saponins, was obtained via hydrolysis of ivy fruit refined extract in ethanolic solution with aqueous HCl.

Hederoside B, the major saponin present in the fruit extract, was obtained by gravity chromatography (Fluorochem, silica gel 40--60, CHCl~3~/MeOH/H~2~O; 90:9:1 → 75:22.5:2.5) of the defatted fruit extract. Fractions containing hederoside B were concentrated and subsequently washed with methanol. Nuclear magnetic resonance data (pyridine-d~5~) of the obtained compound was in agreement with that reported in the literature ([@B9]).

Hederagenin *bis*-esters derivatives (two identical ester moieties at position 3 and 23; **Figure [1](#F1){ref-type="fig"}**) were synthesized from the aglycone hederagenin produced above as described in patent application PCT/EP2016062383 ([@B20]).

![**Structure of Hederagenin derivatives**.](fmicb-08-00399-g001){#F1}

Cholesterol and cholic acid derivatives (**Figure [2](#F2){ref-type="fig"}**) were synthesized following the same methods for esterification of organic molecules, described in patent PCT/EP2016062383 ([@B20]). Hederagenin, cholesterol, and cholic acid derivatives were produced by DSM Nutritional Products and Bangor University.

![**Structure of Cholesterol and Cholic acid derivatives and Hederoside B**.](fmicb-08-00399-g002){#F2}

The purity of the synthesized compounds was established by quantitative nuclear magnetic resonance (qNMR) spectroscopy using a Bruker Ultrashielded 400 spectrometer (Bruker Corporation, Coventry, UK) confirming purities of 80--99% for most derivatives except TSB37 and TSB38 which had a purity of 66 and 58%, respectively. It should be noted that the antiprotozoal activity of compounds TSB37 and TSB38 may be either over or indeed underestimated due to the impurities present.

Measurement of Protozoal Activity
---------------------------------

The effect of hederagenin, cholesterol, and cholic acid derivatives on protozoal activity was measured *in vitro* as the breakdown of \[^14^C\] labeled bacteria by rumen protozoa as described by [@B26]. Isotope-labeled bacteria were obtained by growing *Streptococcus bovis* in Wallace and McPherson media ([@B26]) containing \[^14^C\] leucine (1.89 μCi/7.5 mL tube) as the sole nitrogen source, for 24 h. Cultures were centrifuged (3,000 × *g* for 15 min), supernatant discarded and pellets re-suspended in 7 mL of simplex type salt solution (STS; [@B28]) containing non-labeled leucine (^12^C-leucine, 5 mM). This process was repeated three times to prevent re-incorporation of released \[^14^C\] leucine by bacteria. The labeled bacterial suspension was sampled to determine its radioactivity and then it was used as the substrate in the incubations with rumen fluid.

Rumen digesta was obtained from four rumen-cannulated Holstein-Frisian cows (four replicates), fed at maintenance level (diet composed of perennial ryegrass hay and concentrate at 67:33 on DM basis). Animal procedures were carried out in accordance with the Animal Scientific Procedures Act 1986 and protocols were approved by the Aberystwyth University Ethical Committee. Rumen digesta was obtained before the morning feeding and strained through two layers of muslin and diluted with STS (1:1). Diluted rumen fluid (7.5 mL) was then incubated with labeled bacteria (0.5 mL) in tubes containing no additive (control) or 0.05, 0.1, 0.5, or 1 g/L of the modified triterpenes or steroids; hederoside B, a natural saponin isolated from ivy fruit, was also incubated at 0.05, 0.1, 0.5, and 1 g/L. Hederagenin *bis*-sulfate disodium salt (TSB38), cholesteryl succinate (TSB39), and lithocholic acid succinate (TSB42) were dissolved in dimethyl sulfoxide (DMSO) at 1% of the incubation volume. The rest of the derivatives and Hederoside B were solubilized in ethanol at 1% of the incubation volume as it has been shown that such concentration of ethanol in rumen fluid should not impair fermentation ([@B12]; [@B25]). Two control treatments with 1% of either DMSO or ethanol were also included in the experimental design. Incubations were carried out at 39°C under a stream of CO~2~ and tubes were sampled at time 0 and at 1 h intervals up to 5 h using a syringe with a 19 gauge needle. Samples (0.5 mL) were acidified \[by adding 125 μL of 25% (wt/vol) trichloroacetic acid and centrifuged (13,000 × *g* for 5 min). Supernatant (200 μL), was diluted with 2 mL of scintillation fluid to determine the radioactivity released by liquid-scintillation spectrometry (Hidex 300 SL, Lablogic Systems Ltd, Broomhill, UK\]. Bacterial breakdown at each incubation time was expressed as the percentage of the acid-soluble radioactivity released relative to the total radioactivity present in the initial labeled bacteria ([@B26]).

*In vitro* Batch Cultures
-------------------------

The initial protozoal population in the inoculum used in the incubations was quantified by optical microscope using the procedure described by [@B4] and adapted by [@B3]. Within the total population (5.34 log cells/mL), 65% were *Entodinium*, 8% Epidinium, 21% *Diplodinium*, 3% *Isotricha*, and 3% *Dasytricha*.

To estimate the stability of the antiprotozoal effect and measure the influence of the modified triterpene and steroids on fermentation parameters, strained rumen fluid from each cow was diluted 1:2 in artificial saliva solution ([@B11]). Aliquots (30 mL) of the diluted strained rumen fluid were added anaerobically to 120 mL serum bottles (Sigma-Aldrich Ltd, Dorset, UK) containing 0.3 g of diet composed of ryegrass hay and barley (40:60), previously ground to pass through a 1-mm^2^ mesh screen. Treatments consisted of control incubations (0.3 g of diet only), with either ethanol or DMSO added at 1%, and incubations with the synthesized compounds (diluted in ethanol or DMSO, as previously described) at 0.5 or 1 g/L of the incubation. To compare the antiprotozoal effect of the synthesized compounds against that of a natural saponin from ivy, hederoside B (dissolved in ethanol) was incubated at 1 g/L. Bottles were incubated at 39°C under CO~2~ receiving a gentle mix before every sampling time. Samples at different time points (0, 4, 8, and 24 h) were collected for visual assessment of protozoa motility. Ciliate protozoa motility was assessed in 30 μL of sample against a common scale when examined at low magnification (100×) using light microscopy. This evaluation was conducted in less than 1 min/sample to avoid the cell damage originated by the oxygen and temperature exposure. A score between 0 (no whole protozoa evident) and 5 (all genera active) was given according to the scale described by [@B13]. Fermentation pattern, in terms of pH and VFA was determined after 24 h of the incubation. A subsample (4 mL) was diluted with 1 mL of deproteinizing solution (200 mL/L orthophosphoric acid containing 20 mmol/L of 2-ethylbutyric acid as an internal standard) for the determination of VFA using gas chromatography ([@B21]).

Calculations and Statistical Analysis
-------------------------------------

A simple linear regression was conducted to model the relationship between the percentage of radioactivity released (relative to the ^14^C-bacterial inoculum) and the time (from 0 h to 5 h), as well as its correlation coefficient. The slope of this trend-line indicated the bacterial degradation rate (as % h^-1^) by the rumen protozoa and ultimately their activity. Trend line slopes as well as fermentation parameters were analyzed statistically by randomized block ANOVA, with individual cows as a blocking term. Inhibition of protozoa activity (% with respect to the control) was analyzed using ANOVA with treatment, dose and their interaction as fixed effects and cow as blocking term. When significant effects were detected across the different doses, means were compared by Fisher's unprotected LSD test.

Protozoal motility was analyzed as a Repeated Measures Design, with treatment as main factor and incubation time as subject factor. A stability index, to estimate the persistence of the saponin effect over time, was calculated as the percentage of the motility at 8 h that remained at 24 h. Interaction between treatment and time as a measure of differential temporal dynamics between treatments was also considered. Differences were declared significant at *P* \< 0.05 and considered as tendencies toward significance at *P* \< 0.10. Genstat 15th Edition (VSN International, Hemel Hempstead, UK) was used.

Results
=======

Acute Anti-protozoal Activity
-----------------------------

The amount of bacteria degraded by protozoa increased linearly (*R*^2^ \> 0.99) over the 5 h of incubation with both control treatments (with ethanol or with DMSO). For each derivative, the rate of bacterial degradation at different doses as compared with the control is shown in Supplemental Table [S1](#SM1){ref-type="supplementary-material"}. The inhibition of protozoa activity (**Table [1](#T1){ref-type="table"}**) was significantly different between compounds and doses (*P* \< 0.001). Derivatives TSB44, TSB45, TSB46, TSB47, TSB52, and TSB42 were more effective in inhibiting protozoa activity than hederoside B, the major ivy saponin. Among the cholesterol and cholic acid derivatives, TSB39, TSB40, and TSB43 were less effective against protozoa than the natural saponin (*P* \< 0.001).

###### 

Inhibition of protozoa activity (% in respect to the control, no addition) by hederagenin and bile acid derivatives, added at 0.05, 0.1, 0.5, or 1 g/L.

                                                                       Dose (g/L)                 
  -------------------------------------------------------------------- ------------ ------ ------ ------
  Hederoside B                                                         5.11         22.0   86.0   84.6
  **Hederagenin derivatives**                                                                     
  TSB24: Hederagenin *bis*-succinate                                   5.72         18.8   96.5   100
  TSB33: Hederagenin *bis*-(methylethylenglycolacetate)                13.6         29.7   51.3   64.5
  TSB34: Hederagenin *bis*-(MeO-PEG4-carbonate)                        7.69         14.1   65.5   69.6
  TSB35: Hederagenin *bis*-glutarate                                   7.69         36.0   95.5   93.1
  TSB36: Hederagenin *bis*-glycincarbamate                             0.55         6.19   55.3   93.8
  TSB37: Hederagenin *bis*-betainate dichloride                        16.9         29.1   90.9   94.2
  TSB38: Hederagenin *bis*-sulfate disodium salt                       1.32         4.07   47.9   83.9
  TSB44: Hederagenin *bis*-lactate                                     39.1         86.5   98.3   98.4
  TSB45: Hederagenin *bis*-(2,2-dimethylsuccinate)                     63.1         93.6   96.9   97.8
  TSB46: Hederagenin bis-(3,3-dimethylglutarate)                       75.3         93.0   97.2   96.7
  TSB47: Hederagenin *bis*-adipate                                     29.6         78.1   98.0   94.0
  TSB50: Hederagenin-*bis*-(diglycolate)                               1.06         8.45   75.3   74.3
  TSB51: Hederagenin *bis*-(diglycinate)                               1.74         0.29   54.2   63.8
  TSB52: Hederagenin *bis*-(3,3-dimethylsuccinate)                     66.7         95.2   98.8   98.4
  TSB58: Hederagenin *bis*-[L-]{.smallcaps}tartrate monomethyl ester   0            4.1    95.2   98.2
  **Cholesterol and Cholic acid derivatives**                                                     
  TSB39: Cholesteryl succinate                                         6.42         18.2   17.7   17.6
  TSB40: Cholic succinate                                              25.2         23.5   26.5   42.6
  TSB41: Cholic tri-succinate                                          26.4         21.9   32.9   67.1
  TSB42: Lithocholic succinate                                         75.1         92.8   97.5   97.4
  TSB43: Chenodesoxycholic *bis*-succinate                             1.68         5.66   15.5   53.4
  SED Treatment                                                        4.94^∗∗∗^                  
  Dose                                                                 2.16^∗∗∗^                  
  Treatment × Dose                                                     9.88^∗∗∗^                  

SED, Standard error of the difference;

∗∗∗

P

\< 0.001

.

Stability of the Antiprotozoal Effect and Effect on Fermentation Parameters
---------------------------------------------------------------------------

Based on the observed effects of the synthesized compounds on bacterial breakdown by protozoa, the two highest doses of these derivatives (0.5 and 1 g/L) and hederoside B at 1 g/L, were tested over 24 h in *in vitro* incubations. Protozoa motility over time was assessed and fermentation parameters were determined after 24 h of incubation. Due to the number of compounds tested, the experiment was carried out in different batches and hence the slightly different values for fermentation parameters between control incubations. To overcome this issue, we have compared the effects of each compound against the control run with the same batch of rumen fluid.

Cell motility, measured as an index of protozoa viability, remained unaltered (score of 4.8) over the 24 h incubation period in control incubations with ethanol or DMSO (**Figures [3](#F3){ref-type="fig"}**, **[4](#F4){ref-type="fig"}**). The effect of hederagenin derivatives when added at 0.5 g/L or 1 g/L is shown in **Figures [3A,B](#F3){ref-type="fig"}**, respectively. Although, 1 g/L of hederoside B decreased protozoa motility at 4 and 8 h of the incubation (with scores of 3.88 and 3.20, respectively), there was a strong treatment × time interaction (*P* = 0.05), and protozoal motility recovered afterward (reaching a score of 4.26 at 24 h), suggesting the expected degradation of the saponin during the incubation. Some of the derivatives, TSB45 and TSB46, showed the same effect as the natural saponin, initially decreasing protozoa motility but with motility recovering after 24 h (treatment × time interaction, *P* \< 0.05). Other derivatives, TSB24, TSB47, and TSB52, added at 1 g/L, however, resulted in a greater decrease in protozoa activity over time (*P* \< 0.001; scores of around 3; no motility or activity evident) with no sign of recovery in motility. Indeed, vacuoles were visible at 24 h suggesting protozoal death (scores of 2.15--2.9). Only few of the hederagenin derivatives (TSB33, TSB34, TSB38, and TSB44) did not show an effect on protozoa motility (*P* \> 0.05) at any of the concentrations tested. Cholesterol and cholic acid derivatives did not seem to be effective in reducing protozoa motility over time as shown in **Figure [4](#F4){ref-type="fig"}**. Only TSB42 when added at 1 g/L showed a slight decrease in protozoa motility after 8 and 24 h of incubation (treatment x time interaction, *P* = 0.017; **Figure [4B](#F4){ref-type="fig"}**). A stability index, to estimate the persistence of the saponin effect over time, was calculated as the percentage of the motility at 8 h that remained at 24 h (**Figure [5](#F5){ref-type="fig"}**). Whereas the compounds located above the origin on the *y*-axis were stable (persistent effect on protozoal motility at 24 h; e.g., TS24, TSB37, TSB47), those below the origin on the y-axis showed a loss of effect on protozoal motility (recovery of motility after 24 h; e.g., TSB35, TSB46, hederoside B). The derivatives close to or on the origin of the *y*-axis (e.g., TSB50, TSB51) correspond to those compounds that were less effective against protozoa (scores of about 4.5 at 8 h) but with an effect that was maintained at 24 h.

![**Protozoa motility over 24 h in the absence (control) or presence of different hederagenin derivatives at 0.5 (A)** and 1 g/L **(B)**. Hederoside B was used as a positive control at 1 g/L. Error bars indicate the standard error of the difference for each time point (*n* = 4).](fmicb-08-00399-g003){#F3}

![**Protozoa motility over 24 h in the absence (control) or presence of different cholesterol and cholic acid derivatives at 0.5 (A)** and 1 g/L **(B)**. Hederoside B was used as a positive control at 1 g/L. Error bars indicate the standard error of the difference for each time point (*n* = 4).](fmicb-08-00399-g004){#F4}

![**Stability index (calculated as the percentage of the motility at 8 h that remained at 24 h) against motility scores at 8 h in the presence of hederagenin and cholesterol and cholic acid derivatives and hederoside B (HB) at 1 g/L**. Error bars indicate the standard error of the difference (*n* = 4).](fmicb-08-00399-g005){#F5}

Neither the natural saponin, hederoside B, nor the modified triterpenes or steroids caused a decrease in pH (*P* \> 0.05; **Table [2](#T2){ref-type="table"}**); indeed, pH was slightly greater in the presence of TSB35 and TSB37 at 0.5 and 1 g/L (*P* \< 0.001) in comparison to the control. Similarly, no effect on the concentration of total VFA was observed in incubations with hederoside B or with most of the derivatives (*P* \> 0.05; **Table [3](#T3){ref-type="table"}**). Only TSB35 and TSB36 caused a reduction in the concentration of VFA (*P* \< 0.05) when added at 0.5 and 1 g/L. Also, some of the derivatives decreased the molar proportion of acetate (**Table [4](#T4){ref-type="table"}**; *P* \< 0.05). Almost all treatments caused shifts in the molar proportions of VFA toward lower butyrate and higher propionate (*P* \< 0.05), to different extents depending on the compound (**Tables [5](#T5){ref-type="table"}**, **[6](#T6){ref-type="table"}**).

###### 

Effect of Hederagenin and bile acid derivatives, added at 0.5 or 1 g/L, on pH after 24 h of incubation (batch culture).

                                                                       Dose g/L                               
  -------------------------------------------------------------------- ---------- --------- --------- ------- ---------
                                                                                  pH                          
  Hederoside B                                                         6.03       --        6.09      0.048   0.253
  **Hederagenin derivatives**                                                                                 
  TSB24: Hederagenin *bis*-succinate                                   6.16       6.11      6.15      0.039   0.493
  TSB33: Hederagenin *bis*- (methylethylenglycolacetate)               6.31       6.32      6.31      0.009   0.824
  TSB34: Hederagenin *bis*-(MeO-PEG4-carbonate)                        6.31       6.31      6.31      0.013   0.924
  TSB35: Hederagenin *bis*-glutarate                                   6.31^a^    6.38^b^   6.38^b^   0.019   0.017
  TSB36: Hederagenin *bis*-glycincarbamate                             6.31       6.32      6.29      0.019   0.39
  TSB37: Hederagenin *bis*-betainate dichloride                        6.31^a^    6.36^b^   6.39^c^   0.008   \<0.001
  TSB38: Hederagenin *bis*-sulfate disodiumsalt                        6.41       6.39      6.40      0.014   0.385
  TSB44: Hederagenin *bis*-lactate                                     6.03       6.04      6.04      0.031   0.874
  TSB45: Hederagenin *bis*-(2,2-dimethylsuccinate)                     6.03^a^    6.12^b^   6.12^b^   0.033   0.051
  TSB46: Hederagenin *bis*-(3,3-dimethylglutarate)                     6.16       6.11      6.10      0.034   0.32
  TSB47: Hederagenin *bis*-adipate                                     6.16       6.11      6.15      0.043   0.567
  TSB50: Hederagenin *bis*-(diglycolate)                               6.16       6.10      6.11      0.036   0.294
  TSB51: Hederagenin *bis*-(diglycinate)                               6.16       6.06      6.10      0.038   0.122
  TSB52: Hederagenin *bis*-(3,3-dimethylsuccinate)                     6.16       6.14      6.16      0.042   0.834
  TSB58: Hederagenin *bis*-[L]{.smallcaps}-tartrate monomethyl ester   6.16       6.12      6.12      0.034   0.464
  **Cholesterol and Cholic acid derivatives**                                                                 
  TSB39: Cholesteryl succinate                                         6.18       6.20      6.18      0.031   0.74
  TSB40: Cholic succinate                                              6.03       6.06      6.06      0.026   0.419
  TSB41: Cholic tri-succinate                                          6.03       6.04      6.00      0.019   0.263
  TSB42: Lithocholic succinate                                         6.18       6.19      6.18      0.020   0.876
  TSB43: Chenodesoxycholic *bis*-succinate                             6.03       6.05      6.03      0.021   0.508

a-c

Means with different superscript differ (

n

= 4)

.

###### 

Effect of Hederagenin and bile acid derivatives, added at 0.5 or 1 g/L, on total VFA (mM) after 24 h of incubation (batch culture).

                                                                       Dose g/L                                     
  -------------------------------------------------------------------- ---------------- --------- --------- ------- -------
                                                                       total VFA (mM)                               
  Hederoside B                                                         82.5             --        77.2      3.1     0.185
  **Hederagenin derivatives**                                                                                       
  TSB24: Hederagenin *bis*-succinate                                   70.1             65.4      70.9      4.39    0.448
  TSB33: Hederagenin *bis*-(methylethylenglycolacetate)                80.1             78.6      76.3      3.88    0.647
  TSB34: Hederagenin *bis*-(MeO-PEG4-carbonate)                        80.1             75.0      73.9      4.19    0.355
  TSB35: Hederagenin *bis*-glutarate                                   80.1^b^          68.7^a^   66.7^a^   3.14    0.011
  TSB36: Hederagenin *bis*-glycincarbamate                             80.1^b^          71.2^a^   69.6^a^   3.42    0.045
  TSB37: Hederagenin *bis*-betainate dichloride                        80.1             70.8      72.1      3.34    0.065
  TSB38: Hederagenin *bis*-sulfate disodiumsalt                        74.3             70.6      67.3      6.32    0.568
  TSB44: Hederagenin *bis*-lactate                                     82.5             82.0      82.0      2.04    0.958
  TSB45: Hederagenin *bis*-(2,2-dimethylsuccinate)                     82.5             80.9      73.4      3.47    0.079
  TSB46: Hederagenin *bis*-(3,3-dimethylglutarate)                     70.1             73.8      73.8      3.29    0.467
  TSB47: Hederagenin *bis*-adipate                                     70.1             73.1      70.8      3.16    0.620
  TSB50: Hederagenin *bis*-(diglycolate)                               70.1             73.3      73.3      3.84    0.638
  TSB51: Hederagenin *bis*-(diglycinate)                               70.1             69.7      74.0      3.84    0.503
  TSB52: Hederagenin *bis*-(3,3-dimethylsuccinate)                     70.1             69.5      71.3      4.49    0.914
  TSB58: Hederagenin *bis*-[L]{.smallcaps}-tartrate monomethyl ester   70.1             71.9      72.3      3.64    0.811
  **Cholesterol and Cholic acid derivatives**                                                                       
  TSB39: Cholesteryl succinate                                         72.5             72.5      73.3      0.579   0.333
  TSB40: Cholic succinate                                              82.5             80.4      81.3      2.48    0.704
  TSB41: Cholic tri-succinate                                          82.5             81.5      79.1      2.85    0.512
  TSB42: Lithocholic succinate                                         72.5             73.0      66.5      2.46    0.070
  TSB43: Chenodesoxycholic *bis*-succinate                             82.5             78.9      77.3      2.98    0.279

a,b

Means with different superscript differ (

n

= 4)

.

###### 

Effect of Hederagenin and bile acid derivatives, added at 0.5 or 1 g/L, on Acetate (%) after 24 h of incubation (batch culture).

                                                                       Dose g/L                                             
  -------------------------------------------------------------------- ------------------------ --------- --------- ------- ---------
                                                                       Acetate % of total VFA                               
  Hederoside B                                                         64.8                     --        59.8      0.681   0.005
  **Hederagenin derivatives**                                                                                               
  TSB24: Hederagenin *bis*-succinate                                   64.1^b^                  62.1^b^   59.4^a^   0.837   0.004
  TSB33: Hederagenin *bis*- (methylethylenglycolacetate)               66.1                     65.3      65.2      0.435   0.148
  TSB34: Hederagenin *bis*-(MeO-PEG4-carbonate)                        66.1                     65.4      65.2      0.575   0.31
  TSB35: Hederagenin *bis*-glutarate                                   66.1^c^                  60.2^b^   57.2^a^   0.468   \<0.001
  TSB36: Hederagenin *bis*-glycincarbamate                             66.1^b^                  64.7^a^   64.1^a^   0.472   0.012
  TSB37: Hederagenin *bis*-betainate dichloride                        66.1^c^                  65.5^b^   58.3^a^   0.751   \<0.001
  TSB38: Hederagenin *bis*-sulfate disodiumsalt                        62.3                     62.7      61.8      0.502   0.259
  TSB44: Hederagenin *bis*-lactate                                     64.8                     65.4      65.3      0.964   0.787
  TSB45: Hederagenin *bis*-(2,2-dimethylsuccinate)                     64.8^b^                  61.7^a^   61.1^a^   1.177   0.041
  TSB46: Hederagenin *bis*-(3,3-dimethylglutarate)                     64.1^b^                  61.6^a^   60.3^a^   0.767   0.007
  TSB47: Hederagenin *bis*-adipate                                     64.1^c^                  59.1^b^   56.8^a^   0.875   \<0.001
  TSB50: Hederagenin *bis*-(diglycolate)                               64.1                     64.4      65.2      1.071   0.582
  TSB51: Hederagenin *bis*-(diglycinate)                               64.1                     65.6      64.7      0.77    0.207
  TSB52: Hederagenin *bis*-(3,3-dimethylsuccinate)                     64.1^b^                  60.8^a^   60.3^a^   0.827   0.008
  TSB58: Hederagenin *bis*-[L]{.smallcaps}-tartrate monomethyl ester   64.1                     65.5      65.3      0.841   0.244
  **Cholesterol and cholic acid derivatives**                                                                               
  TSB39: Cholesteryl succinate                                         61.8                     61.8      61.8      0.19    0.993
  TSB40: Cholic succinate                                              64.8                     65.0      64.7      0.941   0.948
  TSB41: Cholic tri-succinate                                          64.8                     65.5      64.9      1.02    0.744
  TSB42: Lithocholic succinate                                         61.8^b^                  61.2^b^   60.1^a^   0.322   0.005
  TSB43: Chenodesoxycholic *bis*-succinate                             64.8^b^                  64.4^b^   61.1^a^   1.25    0.047

a-c

Means with different superscript differ (

n

= 4)

.

###### 

Effect of Hederagenin and bile acid derivatives, added at 0.5 or 1 g/L, on Propionate (%) after 24 h of incubation (batch culture).

                                                                       Dose g/L                                                 
  -------------------------------------------------------------------- --------------------------- ---------- --------- ------- ---------
                                                                       Propionate % of total VFA                                
  Hederoside B                                                         20.1                        --         27.2      1.04    0.006
  **Hederagenin derivatives**                                                                                                   
  TSB24: Hederagenin *bis*-succinate                                   18.3^a^                     25.9^b^    30.5^c^   1.13    \<0.001
  TSB33: Hederagenin *bis*-(methylethylenglycolacetate)                18.6^a^                     19.7^ab^   20.3^b^   0.516   0.038
  TSB34: Hederagenin *bis*-(MeO-PEG4-carbonate)                        18.6^a^                     20.1^ab^   20.8^b^   0.715   0.05
  TSB35: Hederagenin *bis*-glutarate                                   18.6^a^                     28.0^b^    31.4^c^   0.781   \<0.001
  TSB36: Hederagenin *bis*-glycincarbamate                             18.6^a^                     20.7^b^    22.5^c^   0.683   0.004
  TSB37: Hederagenin *bis*-betainate dichloride                        18.6^a^                     24.9^b^    30.6^c^   1.12    \<0.001
  TSB38: Hederagenin *bis*-sulfate disodiumsalt                        20.9^a^                     22.3^a^    24.5^b^   0.575   0.002
  TSB44: Hederagenin *bis*-lactate                                     20.1                        19.5       20.5      1.10    0.632
  TSB45: Hederagenin *bis*-(2,2-dimethylsuccinate)                     20.1^a^                     27.2^b^    28.3^b^   1.44    0.002
  TSB46: Hederagenin *bis*-(3,3-dimethylglutarate)                     18.3^a^                     27.4^b^    28.9^b^   0.984   \<0.001
  TSB47: Hederagenin *bis*-adipate                                     18.3^a^                     30.4^b^    33.7^c^   1.00    \<0.001
  TSB50: Hederagenin *bis*-(diglycolate)                               18.3^a^                     20.2^b^    20.5^b^   0.698   0.041
  TSB51: Hederagenin *bis*-(diglycinate)                               18.3^a^                     19.8^b^    22.4^c^   0.496   \<0.001
  TSB52: Hederagenin *bis*-(3,3-dimethylsuccinate)                     18.3^a^                     28.6^b^    29.7^b^   1.18    \<0.001
  TSB58: Hederagenin *bis*-[L]{.smallcaps} tartrate monomethyl ester   18.3^a^                     19.0^a^    20.9^b^   0.579   0.011
  **Cholesterol and Cholic acid derivatives**                                                                                   
  TSB39: Cholesteryl succinate                                         21.0                        20.8       21.0      0.167   0.458
  TSB40: Cholic succinate                                              20.1                        19.7       20.5      1.139   0.817
  TSB41: Cholic tri-succinate                                          20.1                        19.1       19.6      0.961   0.643
  TSB42: Lithocholic succinate                                         21.0^a^                     22.8^b^    25.0^c^   0.559   0.001
  TSB43: Chenodesoxycholic *bis*-succinate                             20.1                        20.6       23.9      1.476   0.079

a-c

Means with different superscript differ (

n

= 4)

.

###### 

Effect of Hederagenin and bile acid derivatives, added at 0.5 or 1 g/L, on Butyrate (%) after 24 h of incubation (batch culture).

                                                                       Dose g/L                                               
  -------------------------------------------------------------------- ------------------------- ---------- --------- ------- ---------
                                                                       Butyrate % of total VFA                                
  Hederoside B                                                         12.1                      --         9.83      0.427   0.013
  **Hederagenin derivatives**                                                                                                 
  TSB24: Hederagenin *bis*-succinate                                   14.3                      8.8        7.2       0.606   \<0.001
  TSB33: Hederagenin *bis*-(methylethylenglycolacetate)                11.7                      11.5       11.1      0.25    0.1
  TSB34: Hederagenin *bis*-(MeO-PEG4-carbonate)                        11.7^b^                   11.2^ab^   10.7^a^   0.231   0.017
  TSB35: Hederagenin *bis*-glutarate                                   11.7^b^                   7.92^a^    7.54^a^   0.253   \<0.001
  TSB36: Hederagenin *bis*-glycincarbamate                             11.7^c^                   11.2^b^    10.1^a^   0.150   \<0.001
  TSB37: Hederagenin *bis*-betainate dichloride                        11.7^c^                   9.17^b^    7.70^a^   0.375   \<0.001
  TSB38: Hederagenin *bis*-sulfate disodiumsalt                        12.8^c^                   11.3^b^    10.2^a^   0.4     0.002
  TSB44: Hederagenin *bis*-lactate                                     12.1^b^                   11.7^b^    11.0^a^   0.173   0.003
  TSB45: Hederagenin *bis*-(2,2-dimethylsuccinate)                     12.1^b^                   7.74^a^    7.62^a^   0.394   \<0.001
  TSB46: Hederagenin *bis*-(3,3-dimethylglutarate)                     14.3^b^                   8.26^a^    7.76^a^   0.571   \<0.001
  TSB47: Hederagenin *bis*-adipate                                     14.3^b^                   7.35^a^    6.78^a^   0.608   \<0.001
  TSB50: Hederagenin *bis*-(diglycolate)                               14.3^b^                   12.6^a^    11.7^a^   0.506   0.005
  TSB51: Hederagenin *bis*-(diglycinate)                               14.3^b^                   11.7^a^    10.2^a^   0.606   0.001
  TSB52: Hederagenin *bis*-(3,3-dimethylsuccinate)                     14.3^b^                   7.86^a^    7.33^a^   0.746   0.001
  TSB58: Hederagenin *bis*-[L]{.smallcaps}-tartrate monomethyl ester   14.3^c^                   12.5^b^    11.2^a^   0.383   \<0.001
  **Cholesterol and Cholic acid derivatives**                                                                                 
  TSB39: Cholesteryl succinate                                         12.9                      13.0       12.8      0.094   0.341
  TSB40: Cholic succinate                                              12.1^b^                   11.8^b^    11.3^a^   0.178   0.013
  TSB41: Cholic tri-succinate                                          12.1                      12.0       12.1      0.322   0.938
  TSB42: Lithocholic succinate                                         12.9^c^                   11.4^b^    10.2^a^   0.257   \<0.001
  TSB43: Chenodesoxycholic *bis*-succinate                             12.1^c^                   11.5^b^    10.9^a^   0.176   0.002

a-c

Means with different superscript differ (

n

= 4).

The natural saponin, hederoside B, decreased acetate and butyrate molar proportions by 8 and 18%, respectively, whereas it increased that of propionate by 35%, in comparison to the control. The greatest effect was observed with TSB35 (hederagenin *bis*-glutarate), TSB37 (hederagenin *bis*-betainate dichloride) and TSB47 (hederagenin *bis*-apidate) which, when added at 1 g/L, decreased the molar proportion of acetate and butyrate by 11--13.5% and 35.5--52.7%, respectively, with an increase in propionate of 64.5--84.2%. Cholesteryl succinate (TSB39) and cholic tri-succinate (TSB41) did not have any effect on the molar proportions of VFA. Cholic succinate (TSB40) caused only a slight decrease in butyrate (*P* = 0.013) at 1 g/L, as compared to the control. TSB42 and TSB43 also resulted in decreases in acetate and butyrate and increases in propionate although to a lesser extent than those caused by hederoside B. Molar proportions of branched-chain VFA (BCVFA, i.e., isobutyrate and isovalerate) decreased (*P* \< 0.05) in incubations with TSB24 (--13%) and TSB38 (-16%) at 1 g/L and TSB50, TSB51, TSB52, and TSB58 at 0.5 and 1 g/L (decreases of 22--24% at 1 g/L; **Table [7](#T7){ref-type="table"}**). TSB43, however, resulted in an increase (*P* = 0.044) in BCVFA when added at 1 g/L (+54%; **Table [7](#T7){ref-type="table"}**). This was mainly due to changes in isovalerate rather than isobutyrate (Supplemental Tables [S2](#SM2){ref-type="supplementary-material"}, [S3](#SM3){ref-type="supplementary-material"}).

###### 

Effect of Hederagenin and bile acid derivatives, added at 0.5 or 1 g/L, on branched chain volatile fatty acids (BCVFA) (%) after 24 h of incubation (batch culture).

                                                                       Dose g/L                                             
  -------------------------------------------------------------------- ---------------------- ---------- --------- -------- -------
                                                                       BCVFA % of total VFA                                 
  Hederoside B                                                         1.95                   --         2.08      0.161    0.474
  **Hederagenin derivatives**                                                                                               
  TSB24: Hederagenin *bis*-succinate                                   2.08^b^                1.96^ab^   1.81^a^   0.081    0.045
  TSB33: Hederagenin *bis*-(methylethylenglycolacetate)                2.47                   2.29       2.29      0.126    0.307
  TSB34: Hederagenin *bis*-(MeO-PEG4-carbonate)                        2.47^a^                2.19^ab^   2.11^b^   0.124    0.056
  TSB35: Hederagenin *bis*-glutarate                                   2.47                   2.23       2.65      0.216    0.219
  TSB36: Hederagenin *bis*-glycincarbamate                             2.47                   2.33       2.34      0.229    0.775
  TSB37: Hederagenin *bis*-betainate dichloride                        2.47                   2.26       2.35      0.082    0.103
  TSB38: Hederagenin *bis*-sulfate disodiumsalt                        2.64^b^                2.42^ab^   2.22^a^   0.120    0.032
  TSB44: Hederagenin *bis*-lactate                                     1.95                   2.30       2.07      0.275    0.469
  TSB45: Hederagenin *bis*-(2,2-dimethylsuccinate)                     1.95                   2.36       1.85      0.321    0.305
  TSB46: Hederagenin *bis*-(3,3-dimethylglutarate)                     2.08^b^                1.68^a^    2.01^b^   0.096    0.012
  TSB47: Hederagenin *bis*-adipate                                     2.08                   1.91       1.77      0.166    0.263
  TSB50: Hederagenin *bis*-(diglycolate)                               2.08^b^                1.79^a^    1.62^a^   0.11     0.016
  TSB51: Hederagenin *bis*-(diglycinate)                               2.08^b^                1.69^a^    1.63^a^   0.08     0.003
  TSB52: Hederagenin *bis*-(3,3-dimethylsuccinate)                     2.08^b^                1.59^a^    1.58^a^   0.088    0.002
  TSB58: Hederagenin *bis*-[L]{.smallcaps}-tartrate monomethyl ester   2.08^b^                1.86^b^    1.57^a^   0.091    0.004
  **Cholesterol and Cholic acid derivatives**                                                                               
  TSB39: Cholesteryl succinate                                         3.10                   3.23       3.13      0.261    0.879
  TSB40: Cholic succinate                                              1.95                   2.40       2.45      0.209    0.1
  TSB41: Cholic tri-succinate                                          1.95                   2.30       2.31      0.1772   0.141
  TSB42: Lithocholic succinate                                         3.10                   3.63       3.49      0.191    0.203
  TSB43: Chenodesoxycholic *bis*-succinate                             1.95^a^                2.52^ab^   3.00^b^   0.319    0.044

a-b

Means with different superscript differ (

n

= 4)

.

Discussion
==========

The biological activity of saponins depends not only on the type of aglycone but also on the sugar composition and arrangement ([@B30]). The haemolytic action of saponins is believed to be the result of the affinity of the aglycone moiety for membrane sterols, particularly cholesterol with which they form insoluble complexes. It has been shown that monodesmosidic saponins (a single sugar chain) were generally more active than bidesmosidic ones (two sugar chains) ([@B24]). A further study ([@B2]) testing different hederagenin diglycosides concluded that even the substitution of a monosaccharide with another monosaccharide within the sugar chain may change biological activity of saponins. As far as we know, no studies on the correlation between the haemolytic activity and antiprotozoal activity or on the relationship between saponin structure and antiprotozoal activity in the rumen have been carried out.

Although the antiprotozoal effect of saponins has been consistently shown in *in vitro* studies ([@B29]), it was also found to be transient ([@B15]; [@B23]). This transient nature has been associated to the degradation of saponins, i.e., the cleavage of the glycosidic bonds toward the aglycone leaving the inactive sapogenin behind, by rumen bacteria rather than to the ability of rumen protozoa to become resistant ([@B15]). [@B10] reported the disappearance of saponins from quillaja over time when incubated with buffered rumen fluid, with a reduction of 50% after 12 h and by 100% at 24 h of the incubation. In the present study, we hypothesized that the substitution of the sugar moiety of the saponin with small polar residues would produce sapogen-like analogs that might be resistant to ruminal degradation. Both the acute antiprotozoal activity and the stability of that effect over 24 h of fifteen hederagenin *bis*-esters esterified with two identical groups (**Figure [1](#F1){ref-type="fig"}**), and five cholesterol and cholic acid based derivatives carrying one to three succinate residues (**Figure [2](#F2){ref-type="fig"}**) was evaluated. Our 5 h *in vitro* incubations results showed that, irrespective of their resistance to degradation, some of the hederagenin derivatives were more effective in reducing protozoa activity than the natural saponin hederoside B. The greatest effect was shown with TSB45, TSB46, and TSB52 which reduced protozoa activity by 63--75% when they were incubated at 0.05 g/L. Interestingly among the cholesterol and cholic acid derivatives, TSB39 (cholesteryl succinate) had the lowest antiprotozoal effect and, TSB42 (lithocholic acid succinate) was one of the most effective compounds tested, decreasing protozoa activity by 75% when added at 0.05 g/L. These results agree with the observations of [@B22], who showed that the biological activity that a specific chemical residue may provide is not transferable from one derivative to another. To study if the synthesized derivatives were still effective against protozoa over a longer period of time, *in vitro* incubations were carried out sampling at 0, 4, 8, and 24 h to assess the stability of the derivatives in a mixed rumen population. Derivatives TSB24, TSB47, and TSB52 seemed to be very effective in causing a decrease in protozoa motility over time without recovery after 24 h, contrary to the results observed for hederoside B and the rest of compounds. Surprisingly, none of the cholesterol and cholic acid derivatives showed an effect on protozoa motility. Although TSB42 had a strong effect in bacterial breakdown by protozoa over 5 h of incubation, little effect on protozoa motility was observed in 24 h *in vitro* batch cultures. These results may suggest a quicker degradation, and thus the loss of activity, of this compound by rumen bacteria as compared with other derivatives tested. It is apparent that the compounds that showed a high level of acute toxicity against protozoa were not always the most stable ones over time. A stability index was calculated as the percentage of the 8 h activity that remained after 24 h (**Figure [5](#F5){ref-type="fig"}**). Even though TSB35 reduced protozoa activity by 93% when added at 1 g/L, this compound was among the least stable derivatives. TSB24 and TSB47, however, showed both high toxicity (reduction of protozoa activity of 95--100%) and stability over time.

Most of the hederagenin derivatives did not influence total VFA concentration. However, shifts in the molar proportions of VFA toward lower acetate and butyrate which was compensated by a higher propionate were observed. These changes have been previously reported when using different sources of saponins ([@B29]; [@B17]; [@B8]). The shifts in the molar proportions of butyrate and propionate shown in the presence of TSB35, TSB37, and TSB47 were, however, much greater than those that would have been expected because of defaunation. A recent meta-analysis showed that defaunation decreased butyrate by 22% with no effect on propionate ([@B14]). It should be pointed out that TSB37 was of low purity (66%) and thus, this hederagenin derivative could have been more effective than others with higher purity. However, it is possible that the effects observed in the presence of TSB37 were due to the impurities in this derivative. Although our target in using the synthesized compounds was to control protozoal activity, other microorganisms may also have been directly or indirectly affected by the derivatives resulting in further effects on rumen fermentation. Indeed, a direct effect of saponins on bacteria, probably mediated by disruption of the cell membrane ([@B17],[@B18]; [@B1]), has been reported. Similarly, saponins can exert antifungal activity by the interaction with membrane sterols leading to pore formation and loss of membrane integrity ([@B7]; [@B17],[@B18]).

Clearly modifications in the structure of hederagenin resulted in compounds with different biological activities *in vitro*. Whereas some compounds (TSB24) were more effective in reducing protozoa activity and motility, others (TSB37) caused a substantial increase in propionate. If the effect of these compounds can be confirmed *in vivo*, the use of these modified triterpenes in ruminant nutrition will have the potential to improve the efficiency of nitrogen utilization and decrease methane production thus potential boosting productivity.

Conclusion
==========

Most of the hederagenin *bis*-esters, and in particular hederagenin *bis*-succinate (TSB24), hederagenin *bis*-betainate dichloride (TSB37), and hederagenin *bis*-adipate (TSB47) had a persistent effect against rumen protozoa *in vitro*, shifting the fermentation pattern toward higher propionate and lower butyrate. The confirmation of these effects *in vivo* would help to determine if these novel chemically modified triterpenes could potentially be used in ruminant diets as an effective defaunation agent to, ultimately, increase nitrogen utilization, decrease methane emissions, and enhance animal production.
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